halimi jean-michel (@jm_halimi) 's Twitter Profile
halimi jean-michel

@jm_halimi

Professeur des Universités, Néphrologue, Responsable du Centre d’Excellence Européen d’Hypertension de Tours

ID: 1065924243798585345

calendar_today23-11-2018 11:05:18

14 Tweet

101 Followers

48 Following

Gate.io (@gate_io) 's Twitter Profile Photo
Gate.io
@gate_io

5 hours ago

🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358
Valentin-ℳ (@valentinmaisons) 's Twitter Profile Photo
Valentin-ℳ
@valentinmaisons

a year ago

[🩸1/8] Thread - Pleased to share the 1st article from the 🇫🇷 national consortium 🔰🟢MATRIX🟢🔰 published in Kidney International - (dir. halimi jean-michel) 🩸Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies🩸 kidney-international.org/article/S0085-…

[🩸1/8] Thread - Pleased to share the 1st article from the 🇫🇷 national consortium 🔰🟢MATRIX🟢🔰 published in <a href="/Kidney_Int/">Kidney International</a> - (dir. <a href="/JM_Halimi/">halimi jean-michel</a>) 🩸Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies🩸 kidney-international.org/article/S0085-…
Kidney International (@kidney_int) 's Twitter Profile Photo
Kidney International
@kidney_int

a year ago

Assessment of #epidemiology and outcomes of adult patients with kidney-limited #thromboticmicroangiopathies 🔹 Renal Limited-TMA represents⬆️proportion of TMA pts. 🔹PX is poor. 🔹Anti-C5 therapy rarely used in RL-TMA; its effects remain to be assessed. doi.org/10.1016/j.kint…

Assessment of #epidemiology and outcomes of adult patients with kidney-limited #thromboticmicroangiopathies 🔹 Renal Limited-TMA represents⬆️proportion of TMA pts. 🔹PX is poor. 🔹Anti-C5 therapy rarely used in RL-TMA; its effects remain to be assessed. doi.org/10.1016/j.kint…